Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Completed · Phase 1/Phase 2

Conditions studied: Neoplasm Malignant

In brief

Primary Objective: The purpose of this study was to determine the long term safety and tolerability of SAR245408 and SAR245409 as a monotherapy or as part of a combination regimen in participants who were benefiting from treatment.

Key facts

Study ID

NCT01587040

Run by

Sanofi

People needed

61

Starts

2012-07-20

Expected to finish

2018-05-23

Last updated by the study team

2022-04-19

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• I 01. Males or females enrolled in Phase 1 or Phase 2 studies of SAR245408 or SAR245409 as monotherapy or in combination with other regimens who had completed data collection for the primary endpoint(s) of the parental study or who were being treated beyond the parental study cut-off and meet all the criteria to continue to be treated per the parental protocol.
• I 02. All sexually active participants (male and female) must agreed to continue to use accepted methods of barrier contraception (i.e., condoms) during the course of the study and for 3 months after discontinuation of study treatment. For women of childbearing potential and for men who could father a child, a second method of contraception in addition to a barrier method is recommended. Hormonal contraception should be avoided in participants taking SAR245408 due to possible drug-drug interaction.
• I 03. Female participants of childbearing potential must had a negative pregnancy test at baseline. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had any evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to other causes, including prior chemotherapy, anti-estrogens, or ovarian suppression.

You may not qualify if…

• E 01. The participant discontinued the parental study due to toxicity. E 02. Ongoing Grade 3 or higher Adverse Event (AE). E 03. Ongoing Serious Adverse Event (SAE). E 04. Participants with ongoing dose interruption for any reason unless the participant fulfilled the criteria in the parental protocol for restarting IMP. In such case participant started the treatment-extension study on Day 1 of the initiation period.
• E 05. The participant had any of the following laboratory values ≥ Common Terminology of Adverse Events (CTCAE) Grade 3
• Absolute neutrophil count (ANC),
• Platelet count,
• Hemoglobin,
• Bilirubin,
• Serum creatinine or calculated creatinine clearance,
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST),
• Fasting plasma glucose (FPG),
• Prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT).
• E 06. The participant had a baseline corrected QT interval (QTc) >481 millisecond (msec) or if a participant has had a QTc interval increase of ≥ 60 msec from parental protocol baseline to an absolute value of > 470 msec.
• E 07. The participant had a known allergy or hypersensitivity to components of the study treatment formulation(s).
• E 08. The participant was pregnant or breastfeeding.
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Investigational Site Number 840010 — Birmingham, Alabama, United States
• Investigational Site Number 840009 — Los Angeles, California, United States
• Investigational Site Number 840008 — Los Angeles, California, United States
• Investigational Site Number 840022 — Denver, Colorado, United States
• Investigational Site Number 840104 — Fort Myers, Florida, United States
• Investigational Site Number 840006 — Augusta, Georgia, United States
• Investigational Site Number 840004 — Boston, Massachusetts, United States
• Investigational Site Number 840021 — St Louis, Missouri, United States
• Investigational Site Number 840002 — New Brunswick, New Jersey, United States
• Investigational Site Number 840020 — Canton, Ohio, United States
• Investigational Site Number 840015 — Columbus, Ohio, United States
• Investigational Site Number 840017 — Philadelphia, Pennsylvania, United States
• Investigational Site Number 840007 — Nashville, Tennessee, United States
• Investigational Site Number 840003 — Dallas, Texas, United States
• Investigational Site Number 840005 — San Antonio, Texas, United States
• Investigational Site Number 840018 — Morgantown, West Virginia, United States
• Investigational Site Number 056001 — Leuven, Belgium
• Investigational Site Number 250004 — Montpellier, France
• Investigational Site Number 250003 — Pierre-Bénite, France
• Investigational Site Number 250005 — Rouen, France
• Investigational Site Number 724001 — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.